CIRM Funded Clinical Trials

TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

Disease Area:

Investigator:

Institution:

Tachyon Therapeutics, Inc

CIRM Grant:

CLIN2-14232 (Active)

Award Value:

$6,862,609.00

Trial Sponsor:

Tachyon Therapeutics, Inc

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A